BioNTech Stock Rises After Earnings. Pfizer's Vaccine Partners Is Battling a Covid Downturn.

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 51 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 24%
  • Publisher: 97%

France Nouvelles Nouvelles

France Dernières Nouvelles,France Actualités

Shares have dropped 36% this year as demand for its coronavirus inoculations has fallen.

BioNTech, the German pharmaceutical company that partnered with Pfizer to create a Covid-19 vaccine, posted a surprise earnings beat.

For the third quarter, earnings per share came in at 0.67 euros , compared with analysts’ expectations for a loss in the period. Revenue also topped estimates, at €895 million , though both figures were lower than a year ago. The company also said that it wouldn’t have to take as big a hit on its Covid-19 vaccines as it thought just a few weeks ago. It said it would reduce third-quarter revenues by €508 million after Pfizer reported writedowns on their joint product. It initially said it could be about €900 million.

BioNTech U.S.-listed shares jumped more than 3% in premarket trading. BioNTech stock has declined 36% this year. Pfizer , which reported disappointing earnings last week, was up 0.2% in early trading Monday. Covid-19 vaccine makers have been shunned after their meteoric rise during the pandemic. BioNTech and peers such as Pfizer and Moderna are having trouble convincing investors they are more than one-trick ponies.Write to Brian Swint at brian.swint@barrons.com

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

 /  🏆 3. in FR
 

Merci pour votre commentaire. Votre commentaire sera publié après examen.

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Pfizer Covid Vaccine Partner BioNTech's Stock Is Rising After Earnings BeatShares have dropped 36% this year as demand for its coronavirus inoculations has fallen.
La source: MarketWatch - 🏆 3. / 97 Lire la suite »